Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
Trial details
- Registry ID
- NCT06850727
- Phase
- Phase 2
The FDA approved Vedolizumab on 20 May 2014.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative ColitisNCT06850727 | Odyssey Therapeutics | Phase 2 | Recruiting | 2026-04Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-05-20Day | Vedolizumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125476", "applicant_as_listed_by_fda": "TAKEDA PHARMS USA", "brand_names": ["ENTYVIO"], "active_ingredients": ["VEDOLIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140520", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |